A new study from the University of Southern California’s Leonard D. Schaeffer Center for Health Policy & Economics has found that biosimilars are fulfilling their promise to reduce biologic drug prices. The study focused on Genentech’s breast cancer treatment Herceptin and its five biosimilar competitors that entered the US market starting in 2019. When Herceptin's first biosimilar competitor, Kanjinti, hit the market, its average price dropped around 21%, from $101 to $80 per 10 mg. By Q2 2022, towards the end of the analysis period, biosimilars maintained an average sales price of between 28% and 58% of Herceptin's pre-competition average sales price. Biosimilars also altered prescription patterns.